drugset / Trial / NCT05279846

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

NCT05279846

Phase 3 Unknown 350 enrolled Moberg Pharma AB
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 3 multicenter, double-blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Distal Subungual Onychomycosis (DSO)

Timeline

Start
2022-05-09
Primary completion
2025-01
Completion
2025-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Terbinafine Small molecule Topical

Indications